The Link Between Human Cytomegalovirus (HCMV) and Hypertension

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2010 by Beijing Chao Yang Hospital.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Beijing Chao Yang Hospital
ClinicalTrials.gov Identifier:
NCT01113359
First received: April 27, 2010
Last updated: April 28, 2010
Last verified: April 2010
  Purpose

It has been reported that mouse cytomegalovirus infection alone can elevate the blood pressure in mice. Since HCMV has uniquely evolved with its human host, with little genetic similarity to the animal CMV counterparts, and it only replicates in human, an epidemiological study is required to define the relevance of HCMV infection and expression of hcmv-miRNA-UL112 to the pathogenesis of essential hypertension.

The investigators found that hcmv-miR-UL112, a human cytomegalovirus (HCMV)-encoded miRNA, was highly expressed in the hypertensive patients. Among the top miRNA target predictions, the investigators demonstrate that IRF-1 is a direct target gene of hcmv-miR-UL112, along with MICB that has been previously reported. Both IRF-1 and MICB play critical roles in immuno/inflammatory and anti-infection response. Thus, the investigators speculated that IRF-1 and MICB repression by hcmv-miR-UL112 could be considered a unifying mechanism that evades the host response at several levels: antiviral, inflammatory, and immune. In addition, there is an increasing evidence that IRF-1 may be important in apoptosis, angiogenesis, neointima formation and the pathogenesis of vascular diseases. IRF-1 can up-regulate angiotensin II type 2 receptor (AGTR2) that exerts antiproliferative and proapoptotic actions and affects regulation of blood pressure. It has been reported that the targeted disruption of the mouse AGTR2 gene resulted in a significant increase in blood pressure and increased sensitivity to angiotensin II. The nitric oxide synthase expression and NO synthesis in macrophages and distinct cardiomyocytes are induced and controlled by IRF-1 in response to inflammation, important steps in vascular biology that may improve endothelial function and inhibit smooth muscle cell migration, and a key pathophysiological event in hypertension. Collectively, these reports support a strong relationship between IRF-1 regulation and hypertension, indicating a potential role of hcmv-miR-UL112 and HCMV infection in the pathogenesis of hypertension.Thus, the investigators want to investigate the potential link between HCMV infection and essential hypertension.


Condition
HCMV Infection
Hypertension

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Potential Link Between HCMV Infection and Essential Hypertension

Resource links provided by NLM:


Further study details as provided by Beijing Chao Yang Hospital:

Primary Outcome Measures:
  • The positive rate of HCMV infection in hypertensive patients and healthy control [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • HCMV copies number per ml plasma of hypertensive patients and healthy controls [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

plasma


Estimated Enrollment: 300
Study Start Date: April 2010
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
study group
hypertensive patients
control group
healthy volunteer

  Eligibility

Ages Eligible for Study:   30 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

essential hypertensive patients:

Criteria

Inclusion Criteria:

  • Patients with essential hypertension are assessed for potential secondary causes, for the severity of hypertension, other risk factors and for end-organ damage
  • Aged between 30 to 60 years
  • Untreated (whole day average > 140/90 mmHg) or treated hypertension whole-day average < 140/85), as determined by 24-hour blood pressure monitoring.

Exclusion Criteria:

  • Cancer
  • Diabetes
  • Smoking
  • Renal failure
  • Stroke
  • Peripheral artery disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01113359

Locations
China, Chaoyang
Jun Cai Recruiting
Beijing, Chaoyang, China, 100020
Contact: Jun Cai, MD    +86 10 85231217    caijun7879@yahoo.com.cn   
Sub-Investigator: Jun Cai, MD         
Sponsors and Collaborators
Beijing Chao Yang Hospital
Investigators
Principal Investigator: Xin-Chun Yang, MD Beijing Chao Yang Hospital
  More Information

No publications provided

Responsible Party: Jun Cai / Heart Center, Beijing Chao Yang Hospital
ClinicalTrials.gov Identifier: NCT01113359     History of Changes
Other Study ID Numbers: BJCY-CV-2010001, YXinchun
Study First Received: April 27, 2010
Last Updated: April 28, 2010
Health Authority: China: National Natural Science Foundation

Keywords provided by Beijing Chao Yang Hospital:
HCMV infection
Hypertension
The Potential Link Between HCMV Infection and Essential Hypertension

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on July 20, 2014